PCN19 Cost-Effectiveness Of First-Line Therapy For Advanced Non-Small Cell Lung Cancer (Nsclc)  by Yang, MC & Tan, ECH
A736  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  
chemotherapy. Methods: We performed a systematic literature search of the 
EMBASE, MEDLINE, Cochrane Library, Google Scholar, ABI/Inform, and the Web 
of Science using such search terms “filgrastim,” “pegfilgrastim,” “cost analysis,” 
and “economic evaluation.” Studies were limited to primary research in patients 
with solid tumor cancer, specifically, studies comparing filgrastim with pegfil-
grastim and resulting in full manuscripts. Identified studies were evaluated by 
the Drummond checklist6 and characterized by study perspectives, time horizon, 
data sources, and funding. Results: Six studies fulfilled the inclusion criteria. 
Most studies modeled hypothetical cohorts of women aged 30-80 years with breast 
cancer (Stages I-III) from a payer’s perspective. The median Drummond score was 
9 of 10 (range, 8-9). Methodological and reporting variations were common. Key 
assumptions were made about FN-related deaths during chemotherapy, hospi-
talization and outpatient management, chemotherapy costs, and data sources. All 
six studies were funded by the drug manufacturer. Pegfilgrastim was found to be 
cost-saving compared to 11-day filgrastim. However, when compared to 6-day fil-
grastim, the choice of intervention depends on the decision-maker’s willingness-
to-pay. ConClusions: Variations in methodology, reporting, and assumptions 
made comparisons between studies difficult and may explain in part the observed 
results reported in EEs. Studies independent of industry sponsor are needed to 
make conclusive interpretations.
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objeCtives: Cost-effectiveness analysis and cost-utility analysis were adopted to 
evaluate the tertiary breast cancer screening and diagnosis system in Guangdong 
province. Methods: Using data from Guangdong project to evaluate the validity 
and reliability of screening strategies. The intervention group received tertiary 
screening and diagnosis system, while control group received routine screening. 
The actual cost, detection rate and cost-effectiveness ratio were calculated. The 
Markov simulation model was constructed based on the natural history of breast 
cancer with TreeAge Pro 2011. The model was running over thirty years (each 
cycle represents one year). The sensitivity analysis was performed for incidence of 
breast cancer and health state utility. Results: The intervention group involved 
26224 females while the control group involved 24282. The detection rate of breast 
cancer (1/10 million) was 91.54 and 28.86. The percentage of early stage breast 
cancer was 45.83% and 28.57%, respectively. The highest detection rate was found 
in women aged from 45 to 65. In order to detection one case of breast cancer, 
the number need to invite for screening program was 1595. Cost-effectiveness 
analysis was 6152.37yuan per detection rate of breast cancer (1/10 million). During 
the following 30 years, comparing to the control group, the tertiary breast cancer 
screening and diagnosis system for 100 thousand women will reduce 61 cases of 
breast cancer, and save 557.00 LYs, 649.05 QALYs. With the discount rate of 3%, 
Cost-utility analysis was 8142.33yuan per life year saved, 6987.57yuan per QALY 
saved and 74348.84yuan per breast cancer prevented. One-way sensitivity analysis 
showed that parameters had no significant effect on the model. ConClusions: 
Compared to control group, the screening strategy of intervention group improved 
both the detection rate of breast cancer and the percentage of early stage breast 
cancer. The tertiary breast cancer screening and diagnosis system is a preferable 
option for breast cancer screening.
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objeCtives: Our previous research indicated that post-therapy PET scanning may 
obviate the need for hospital-based follow-up in patients with locally advanced 
cervical cancer who achieved a complete metabolic response (CMR). In these 
patients, asymptomatic recurrences were rarely discovered through examina-
tion in the clinic. The aim of this research is to evaluate the cost-effectiveness of 
applying different follow-up strategies in Australia. Methods: A decision analyti-
cal model was constructed to evaluate cost per quality-adjusted life-year (QALY) 
and life-years gained (LYG) by comparing two follow-up strategies: 1) Routine 
hospital-based follow-up and 2) Alternative follow-up involving post-therapy PET 
and nurse-led telephone interview. A model was built using data from a prospec-
tive institutional registry study of 105 consecutive women underwent definitive 
chemoradiation therapy. Based on published institutional data, it was estimated 
that patients who had a complete metabolic response identified by PET, would 
have 5-year overall-survival of 93% and 1.5% recurrence rate, while those with-
out CMR would have a 5-year overall-survival of only 36%.The impact of uncer-
tainty was evaluated using probabilistic sensitivity analysis. Results: Costs for 
Alternative follow-up was estimated to be $25,657 compared with $19,982 for 
Routine follow-up. Alternative follow-up is not cost-saving; this is because the cost 
of PET screening and additional treatment performed on those without CMR is 
more than offset by the cost of intensive hospital-based visits avoided. Preliminary 
modeling suggest that the Alternative follow-up is likely to be cost-effective com-
pared with Routine follow-up with an ICER of $4,094/QALYs gained, given the sur-
vival benefit associated with better targeted salvage therapy and that this result is 
robust to a range of survival gain estimates and other parameters. ConClusions: 
Performing PET scan to evaluate patient’s risk of recurrence is an appealing pros-
pect. This study demonstrated that the alternative follow-up with post-therapy 
PET is likely to be cost-effective when compared to the current practice.
and varying survival rates according to radiation field. Results: We compared 
two strategies: Strategy 1) pelvic CRT for all patients or Strategy 2) nodal staging 
surgery, then extended-field CRT when PALN metastasis is found; otherwise, pelvic 
CRT. ICER for strategy 2 compared to strategy 1 was $19,505 per quality-adjusted life 
year (QALY). Nodal staging surgery was cost-effective at the $50,000 willingness-to-
pay threshold as long as generous survival reduction (> 17%) is found in patients 
who underwent only pelvic CRT despite occult PALN metastasis. The model was 
insensitive to change in performance of PET/CT and postoperative complication 
rates. ConClusions: Nodal staging surgery before definite CRT is potentially 
cost-effective in Korea when PET/CT shows no evidence of para-aortic lymph node 
metastasis. Prospective trials are warranted to transfer these results into guidelines.
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objeCtives: To assess the cost-effectiveness of Afatinib vs. comparators in the 
first-line treatment for patients with non-small cell lung cancer (NSCLC) harbour-
ing epidermal growth factor receptor (EGFR) mutations. Methods: A cost-effec-
tiveness model was applied to assess the costs and effects of afatinib. Data related 
to medical resource use, efficacy of the drugs and health related quality-of-life 
status came from the clinical studies and supported by the results of a Network 
Meta-Analysis (NMA). Direct cost data was obtained from the Bureau of National 
Health Insurance (BNHI) and NHI claims data released by the Collaboration Center of 
Health Information Application. Outcomes included life-years, quality-adjusted life 
years (QALYs), medical costs and incremental cost-effectiveness ratios (ICERs). The 
single-payer (BNHI) perspective is assumed and costs are expressed in New Taiwan 
dollars (NT$). The discount rate of costs and effects is 5%. Results: Treatment 
with afatinib in the 1st line setting extends time in progression-free survival (PFS). 
Compared to gefitinib, patients treated with afatinib in the 1st line setting have 
an increase of 0.05 quality-adjusted life-years (QALYs) and the additional cost is 
NT$21,350.59, yielding an ICER of NT$457,768.67 per QALY gained. Compared to 
erlotinib, patients treated with afatinib have an increase of 0.02 QALYs with less cost 
of NT$-56,216. ConClusions: The results provide decision makers with informa-
tion about the cost-effectiveness of taking afatinib as first-line therapy for advanced 
stage NSCLC by direct comparison of two EGFR-TKIs and cisplatin/pemetrexed. From 
the perspective of the single payer, the afatinib could be a cost-effectiveness strategy 
compared with erlotinib and gefitinib for the 1st line treatment of advanced NSCLC.
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objeCtives: In this study a comprehensive assessment of the cost-effectiveness 
of lenalidomide-plus-dexamethasone compared to dexamethasone, as second-
line or greater than second-line therapy in relapsed/refractory multiple myeloma 
(rrMM) patients was performed, from the perspective of the South Korean National 
Health System. Methods: A Markov-type model was designed to assess the 
long-term costs and effectiveness of lenalidomide-plus-dexamethasone and 
dexamethasone, using patient-level data from the MM-009/MM-010 randomized 
controlled trials. Due to potential crossover-induced bias by subsequent therapies, 
overall survival (OS) was estimated using a quantitative relationship between 
progression-free-survival and OS (censored normal weighted Tobit regression 
model, based on 153 MM studies containing 230 treatment arms). Only direct costs 
were considered (drugs, adverse events and disease monitoring). Effectiveness 
was measured in life years (LY) and quality-adjusted life years (QALY). Costs were 
converted to United-States dollars (1USD= 1,071.33WON). Annual discount rates 
were set at 5% for costs and effectiveness. Probabilistic sensitivity analysis (PSA) 
was conducted with Monte Carlo simulations. Results: For the patient popula-
tion with one previous therapy lenalidomide-plus-dexamethasone is estimated 
to add substantial benefits to dexamethasone, with expected gains of 1.83QALY 
and 2.50LY, offset by a mean incremental cost of $55,387. Corresponding incre-
mental cost-effectiveness ratios are estimated at $30,195/QALY and $22,148/LY. 
PSA revealed a > 95% probability of lenalidomide-plus-dexamethasone being cost-
effective in comparison to dexamethasone at a $40,000 threshold. These results 
are robust against sensitivity analyses in turns of patient sub-populations and 
different crossover correction techniques (simulated treatment comparison; rank 
preserving structural failure time models). ConClusions: Lenalidomide-plus-
dexamethasone can be regarded a valuable treatment option for second or greater 
line therapy in rrMM patients.
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objeCtives: Evidence suggests that primary prophylaxis with filgrastim 
(Neupogen®, administered daily for 10-11 days per chemotherapy cycle) or peg-
filgrastim (Neulasta®, administered once per chemotherapy cycle) is equally 
effective.1-4 Patients often receive shorter (< 7 days) courses of filgrastim in clini-
cal practice.5 Using filgrastim for fewer days may reduce costs, but it has been 
associated with an increased hospitalization risk.5 Economic evaluations (EEs) may 
be used to guide decisions in resource allocation. The objective of this review is 
to identify and characterize the EEs of primary prophylaxis with filgrastim ver-
sus pegfilgrastim in patients with solid tumor cancer receiving myelosuppressive 
